Medifast (NYSE:MED – Get Free Report) and Unicharm (OTCMKTS:UNICY – Get Free Report) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.
Earnings and Valuation
This table compares Medifast and Unicharm”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medifast | $299.57 million | 0.47 | -$18.67 million | ($3.69) | -3.39 |
| Unicharm | $6.32 billion | 1.96 | $436.93 million | $0.12 | 29.67 |
Unicharm has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Unicharm, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Medifast has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Unicharm has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Medifast and Unicharm, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medifast | 1 | 2 | 0 | 0 | 1.67 |
| Unicharm | 0 | 2 | 0 | 0 | 2.00 |
Medifast presently has a consensus price target of $12.00, suggesting a potential downside of 4.12%. Given Medifast’s higher probable upside, analysts plainly believe Medifast is more favorable than Unicharm.
Profitability
This table compares Medifast and Unicharm’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medifast | -13.64% | -6.90% | -5.34% |
| Unicharm | 6.21% | 6.70% | 4.93% |
Insider and Institutional Ownership
95.5% of Medifast shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Dividends
Medifast pays an annual dividend of $6.60 per share and has a dividend yield of 52.7%. Unicharm pays an annual dividend of $0.04 per share and has a dividend yield of 1.1%. Medifast pays out -178.9% of its earnings in the form of a dividend. Unicharm pays out 33.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medifast is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
Unicharm beats Medifast on 9 of the 15 factors compared between the two stocks.
About Medifast
Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company’s approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company’s programs.
About Unicharm
Unicharm Corporation is a Japanese manufacturer of hygiene and personal care products. Its offerings include baby diapers and related products, feminine care products, and adult incontinence and other healthcare products. The company also sells pet-care products, including pet food and hygiene supplies, as well as household and cleaning products. Unicharm’s brands serve consumers in Japan and international markets, particularly across Asia, with operations and sales spanning additional regions. Founded in Japan in 1961, Unicharm has expanded from its domestic roots into a global consumer-products business.
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.
